Whole-body radiation dosimetry of 2-[18F]Fluoro-A-85380 in human PET imaging studies.
2-[18F]Fluoro-A-85380 (2-[18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine, 2-[18F]FA) is a recently developed PET radioligand for noninvasive imaging of nicotinic acetylcholine receptors. Previous radiation absorbed dose estimates for 2-[18F]FA were limited to evaluation of activity in only several critical organs. Here, we performed 2-[18F]FA radiation dosimetry studies on two healthy human volunteers to obtain data for all important body organs. Intravenous injection of 2.9 MBq/kg of 2-[18F]FA was followed by dynamic PET imaging. Regions of interest were placed over images of each organ to generate time-activity curves, from which we computed residence times. Radiation absorbed doses were calculated from the residence times using the MIRDOSE 3.0 program (version 3.0, ORISE, Oak Ridge, TN). The urinary bladder wall receives the highest radiation absorbed dose (0.153 mGy/MBq, 0.566 rad/mCi, for a 2.4-h voiding interval), followed by the liver (0.0496 mGy/MBq, 0.184 rad/mCi) and the kidneys (0.0470 mGy/MBq, 0.174 rad/mCi). The mean effective dose equivalent is estimated to be 0.0278 mSv/MBq (0.103 rem/mCi), indicating that radiation dosimetry associated with 2-[18F]FA is within acceptable limits.
Obrzut
Sebastian L
SL
Department of Radiology, Division of Nuclear Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Koren
Andrei O
AO
Mandelkern
Mark A
MA
Brody
Arthur L
AL
Hoh
Carl K
CK
London
Edythe D
ED
D000328:Adult; D001384:Azetidines / Q000032:analysis* / Q000493:pharmacokinetics*; D001822:Body Burden; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D009842:Oligopeptides; D009928:Organ Specificity; D049268:Positron-Emission Tomography / Q000379:methods*; D011725:Pyridines / Q000032:analysis* / Q000493:pharmacokinetics*; D011829:Radiation Dosage; D011835:Radiation Protection / Q000379:methods*; D019275:Radiopharmaceuticals / Q000032:analysis / Q000493:pharmacokinetics; D012062:Relative Biological Effectiveness; D014018:Tissue Distribution; D051598:Whole Body Imaging / Q000379:methods; D014915:Whole-Body Counting / Q000379:methods*
C119803:2-fluoro-3-(2-azetidinylmethoxy)pyridine; D001384:Azetidines; D009842:Oligopeptides; D011725:Pyridines; D019275:Radiopharmaceuticals; C074408:85548e